Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

ASH 2024 Summary: Highlights in Adult ALL and Implications for Pract…

2024 ASH Annual Meeting Insights Hub

R. Cassaday

ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

Sarah Tasian

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Indy Hematology Review

H. Erba

ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid D…

2024 ASH Annual Meeting Insights Hub

H. Fernandez

Current Treatment of Younger 1L AML in 2024

Gautam Borthakur

Updates in ALL: Incorporating Immunotherapy in Frontline Management

Talha Badar

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

2024 Updates in AML

University of Colorado Division of Hematology

C. McMahon

Secondary AML: Best Therapy Options

Weill Cornell Medicine Oncology & Hematology

P. Desai

ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independe…

2024 ASH Annual Meeting Insights Hub

J. Watts